ReviewCurrent hematologic malignancy reports2017
Hypomethylating Agents as a Therapy for AML.
Review in Current hematologic malignancy reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia.European journal of medical research · 2025Pooled it
- Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature.Blood advances · 2020Pooled it
- Integrating multi-omics approaches in acute myeloid leukemia (AML): Advancements and clinical implications.Clinical and experimental medicine · 2025Review
- Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia.Cell death & disease · 2024Review
- Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases.Biomolecules · 2023Article
- SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid Leukemia Patients.Current gene therapy · 2023Article
- 5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia.Cancers · 2022Article
- Targeting the integrated stress response in hematologic malignancies.Experimental hematology & oncology · 2022Review
- RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.International journal of molecular sciences · 2022Article
- Spontaneous Remission of Acute Myeloid Leukemia: A Case Report.Medicina (Kaunas, Lithuania) · 2022Article
- Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data.Northern clinics of Istanbul · 2022Article
- Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia.Frontiers in pediatrics · 2022Review
- Review
- Epigenetic Mechanisms in Leukemias and Lymphomas.Cold Spring Harbor perspectives in medicine · 2020Review
- Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence.Journal of clinical medicine · 2020Review
- DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.Leukemia research · 2020Article
- Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis.Nature reviews. Cancer · 2020Review
- A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.Blood advances · 2020Article
- Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness.Cancers · 2020Review
- Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis.Open life sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is predominantly a disease of older adults associated with poor long-term outcomes with available therapies. Used as single agents, hypomethylating agents (HMAs) induce only 15 to 25% complete remissions, but current data suggest that median OS observed after HMAs is comparable to that observed after more intensive therapies. Whether long-term cure may be obtained in some patients treated with HMAs is unknown. Combinations of HMAs to novel agents are now extensively investigated and attractive response rates have been reported when combining HMAs to different drug classes. The absence of reliable predictive biomarkers of efficacy of HMAs in AML and the uncertainties regarding their most relevant mechanisms of action hinder the rational design of the combinations to be tested in priority, usually in untreated older AML patients.
Indexed as
Identifiers
28286907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.